(Q42675706)

4 November 2017

Improving risk assessment (English)

1 reference

4 November 2017

Donna M Dambach

1

1 reference

PubMed ID

23136041

4 November 2017

Hirdesh Uppal

series ordinal

2

1 reference

PubMed ID

23136041

4 November 2017

language of work or name

English

0 references

publication date

1 November 2012

1 reference

Science Translational Medicine

4 November 2017

1 reference

4 November 2017

4

1 reference

4 November 2017

159

1 reference

4 November 2017

159ps22

1 reference

Lessons from 60 years of pharmaceutical innovation

4 November 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Why drugs fail--a study on side effects in new chemical entities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Trial watch: Phase II failures: 2008-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Phase III and submission failures: 2007–2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Reengineering translational science: the time is right

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

First dose of potential new medicines to humans: how animals help

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

From 3D cell culture to organs-on-chips

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Reconstituting organ-level lung functions on a chip

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Development of a microscale cell culture analog to probe naphthalene toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Design and prototyping of a chip-based multi-micro-organoid culture system for substance testing, predictive to human (substance) exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Accelerating the development of 21st-century toxicology: outcome of a Human Toxicology Project Consortium workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

The role of body-on-a-chip devices in drug and toxicity studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Micro total bioassay system for ingested substances: assessment of intestinal absorption, hepatic metabolism, and bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Idiosyncratic drug reactions: current understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

The influence of drug-like concepts on decision-making in medicinal chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003497

10.1126/SCITRANSLMED.3003497

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference

PubMed ID

23136041